1
|
Mori C, Iwamoto E, Kadoi K, Pluskal MG, Matsumoto Y. Impact of ligand structure and base bead pore size on host cell protein removal during monoclonal antibody purification using multimodal chromatography resin. J Chromatogr A 2024; 1732:465202. [PMID: 39079362 DOI: 10.1016/j.chroma.2024.465202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Revised: 07/12/2024] [Accepted: 07/20/2024] [Indexed: 08/23/2024]
Abstract
Despite advancements in therapeutic monoclonal antibodies (mAbs) and cell line engineering, separating host cell proteins (HCPs) from mAbs during downstream purification remains challenging. Therefore, in this study, we developed a novel multimodal chromatography (MMC) resin to enhance HCP removal during mAb polishing processes. We evaluated the impact of both ligand structure and pore size of the MMC resin by purifying a post-protein A chromatography solution in flow-through mode. We observed that the efficiency of HCP clearance depended on the hydrophobic moiety structure of the ligand and predicted the mAb purification capability of MMC through linear salt-gradient elution experiments involving a mixture of transferrin, bovine serum albumin (BSA), and pepsin. Our findings revealed that the prototype immobilized 1,12-dodecanediamine via the formyl group exhibited the best performance attributed to its long alkyl chain. Furthermore, an investigation of effects of base bead pore size on HCP capacity using cellulose base beads of five different pore sizes showed that larger pore resin base beads had the highest HCP removal capacity. Specifically, MMC resins with a pore diameter exceeding 440 nm reduced the HCP level by three orders of magnitude under high mAb loading conditions (> 1000 mg/mL-resin). The MMC resin developed in this study, along with the insights gained into ligand structure and pore size, not only enhances mAb polishing efficiency but also contributes to improving downstream processes in mAb biopharmaceutical production.
Collapse
Affiliation(s)
- Chigusa Mori
- Yokohama R&D Center, JNC CORPORATION, 5-1, Ookawa, Kanazawa-ku, Yokohama, 236-8605, Japan.
| | - Eri Iwamoto
- Yokohama R&D Center, JNC CORPORATION, 5-1, Ookawa, Kanazawa-ku, Yokohama, 236-8605, Japan
| | - Kenji Kadoi
- Yokohama R&D Center, JNC CORPORATION, 5-1, Ookawa, Kanazawa-ku, Yokohama, 236-8605, Japan
| | - Malcolm G Pluskal
- Cellufine Application Lab, JNC America, Inc., 15 John Francis Lane, Acton, MA 01720, United States
| | - Yoshihiro Matsumoto
- Yokohama R&D Center, JNC CORPORATION, 5-1, Ookawa, Kanazawa-ku, Yokohama, 236-8605, Japan
| |
Collapse
|
2
|
Wang Y, Bhaskar U, Chennamsetty N, Noyes S, Guo J, Song Y, Lewandowski A, Ghose S. Hydrophobic interaction chromatography in continuous flow-through mode for product-related variant removal. J Chromatogr A 2024; 1736:465356. [PMID: 39276416 DOI: 10.1016/j.chroma.2024.465356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2024] [Revised: 09/05/2024] [Accepted: 09/06/2024] [Indexed: 09/17/2024]
Abstract
Product-related impurities are challenging to remove during monoclonal antibody (mAb) purification process due to molecular similarity. Frontal chromatography on hydrophobic interaction resins has demonstrated its capability to effectively remove such impurities. However, process improvements geared towards purity level comes as a trade-off with the yield loss. In this work, we present a hydrophobic interaction chromatography process using multicolumn continuous chromatography (MCC) concept and frontal analysis to remove a high prevalence product related impurity. This design uses a two-column continuous system where the two columns are directly connected during product chase step to capture product wash loss without any in-process adjustment. This polish MCC operation resulted in a 10 % increase in yield while maintaining 99 % purity, despite the presence of 20 % product-related impurities in the feed material. One challenge associated with polish MCC design is that the accumulation of the impurities renders a non-steady state recycling. To surmount this issue and ensure a robust process, a mechanistic model was developed and validated to predict multicomponent breakthrough. This model was capable to predict multiple cycle behavior and accounts for increased impurity concentration. Assisted by the model, the optimized operation parameters and conditions can be determined to account for variation in product load quality. The simulated results demonstrate an effective doubling of productivity compared to conventional batch chromatography.
Collapse
Affiliation(s)
- Yiran Wang
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA, USA.
| | - Ujjwal Bhaskar
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA, USA
| | - Naresh Chennamsetty
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA, USA
| | - Steven Noyes
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA, USA
| | - Jing Guo
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA, USA
| | - Yuanli Song
- Genomic Medicine Unit CMC Purification Process Development, Sanofi, Waltham, MA, USA
| | - Angela Lewandowski
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA, USA
| | - Sanchayita Ghose
- Biologics Development, Bristol Myers Squibb, 38 Jackson Road, Devens, MA, USA
| |
Collapse
|
3
|
Brean A, Overton TW, Bracewell DG, Franzreb M, Thomas ORT. Integrated system for temperature-controlled fast protein liquid chromatography. IV. Continuous 'one-column' 'low-salt' hydrophobic interaction chromatography. J Chromatogr A 2024; 1731:465212. [PMID: 39068770 DOI: 10.1016/j.chroma.2024.465212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Revised: 07/23/2024] [Accepted: 07/24/2024] [Indexed: 07/30/2024]
Abstract
Systematic development of a temperature-controlled isocratic process for one-column low-salt hydrophobic interaction chromatography (HIC) of proteins employing a travelling cooling zone reactor (TCZR) system, is described. Batch binding and confocal scanning microscopy were employed to define process conditions for temperature-reversible binding of bovine serum albumin (BSA) which were validated in pulse-response temperature switching HIC experiments, before transferring to TCZR-HIC. A thin-walled stainless-steel column mounted with a movable assembly of copper blocks and Peltier elements (travelling cooling zone, TCZ) was used for TCZR-HIC. In pulse-response TCZR-HIC, 12 TCZ movements along the column desorbed 86.3% of the applied BSA monomers in 95.3% purity depleted >6-fold in 2-4 mers and nearly 260-fold in higher molecular weight (HMW) species. For continuous TCZR-HIC, the TCZ was moved 49-58 times during uninterrupted loading of BSA feeds at 0.25, 0.5 or 1 mg·mL-1. Each TCZ movement generated a sharp symmetrical elution peak. In the best case, (condition 1: 0.25 mg·mL-1 BSA; >17 mg BSA applied per mL of bed) the height of TCZ elution peaks approached pseudo-steady midway through the loading phase with no rise in baseline UV280 signal between peaks. Peak composition remained constant averaging 94.4% monomer, 5.6% 2-4 mers and <0.05% HMW. Monomers were recovered in quantitative yield depleted >3.1 fold in 2-4 mers and 92-fold in HMW species cf. the feed (63.6% monomers, 21.8% 2-4 mers, 14.6% HMW). However, increasing the BSA concentration to 1 mg·mL-1 (condition 2) or employing a fouled HIC column with 0.5 mg·mL-1 BSA (condition 3) compromised monomer purification performance.
Collapse
Affiliation(s)
- Alexander Brean
- School of Chemical Engineering, College of Engineering and Physica1, University of Birmingham, Edgbaston, Birmingham B15 2TT, England, UK
| | - Tim W Overton
- School of Chemical Engineering, College of Engineering and Physica1, University of Birmingham, Edgbaston, Birmingham B15 2TT, England, UK; Institute for Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
| | - Daniel G Bracewell
- Department of Biochemical Engineering, University College London, London WC1E 6BT, UK
| | - Matthias Franzreb
- Institute of Functional Interfaces, Karlsruhe Institute of Technology, Hermann-von-Helmholtz-Platz 1, 76344 Eggenstein-Leopoldshafen, Germany
| | - Owen R T Thomas
- School of Chemical Engineering, College of Engineering and Physica1, University of Birmingham, Edgbaston, Birmingham B15 2TT, England, UK.
| |
Collapse
|
4
|
Lorek JK, Karkov HS, Matthiesen F, Dainiak M. High throughput screening for rapid and reliable prediction of monovalent antibody binding behavior in flowthrough mode. Biotechnol Bioeng 2024; 121:2332-2346. [PMID: 37926999 DOI: 10.1002/bit.28572] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 09/11/2023] [Accepted: 09/21/2023] [Indexed: 11/07/2023]
Abstract
Flowthrough (FT) anion exchange (AEX) chromatography is a widely used polishing step for the purification of monoclonal antibody (mAb) formats. To accelerate downstream process development, high throughput screening (HTS) tools have proven useful. In this study, the binding behavior of six monovalent mAbs (mvAbs) was investigated by HTS in batch binding mode on different AEX and mixed-mode resins at process-relevant pH and NaCl concentrations. The HTS entailed the evaluation of mvAb partition coefficients (Kp) and visualization of results in surface-response models. Interestingly, the HTS data grouped the mvAbs into either a strong-binding group or a weak-binding/FT group independent of theoretical Isoelectric point. Mapping the charged and hydrophobic patches by in silico protein surface property analyses revealed that the distribution of patches play a major role in predicting FT behavior. Importantly, the conditions identified by HTS were successfully verified by 1 mL on-column experiments. Finally, employing the optimal FT conditions (7-9 mS/cm and pH 7.0) at a mini-pilot scale (CV = 259 mL) resulted in 99% yield and a 21-23-fold reduction of host cell protein to <100 ppm, depending on the varying host cell protein (HCP) levels in the load. This work opens the possibility of using HTS in FT mode to accelerate downstream process development for mvAb candidates in early research.
Collapse
Affiliation(s)
| | | | - Finn Matthiesen
- Purification Technologies, Novo Nordisk A/S, Maaloev, Denmark
| | - Maria Dainiak
- Purification Technologies, Novo Nordisk A/S, Maaloev, Denmark
| |
Collapse
|
5
|
Nolan D, Chin TR, Eamsureya M, Oppenheim S, Paley O, Alves C, Parks G. Modeling the behavior of monoclonal antibodies on hydrophobic interaction chromatography resins. BIORESOUR BIOPROCESS 2024; 11:25. [PMID: 38647931 PMCID: PMC10991917 DOI: 10.1186/s40643-024-00738-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Accepted: 02/01/2024] [Indexed: 04/25/2024] Open
Abstract
Monoclonal antibodies (mAbs) require a high level of purity for regulatory approval and safe administration. High-molecular weight (HMW) species are a common impurity associated with mAb therapies. Hydrophobic interaction chromatography (HIC) resins are often used to remove these HMW impurities. Determination of a suitable HIC resin can be a time and resource-intensive process. In this study, we modeled the chromatographic behavior of seven mAbs across 13 HIC resins using measurements of surface hydrophobicity, surface charge, and thermal stability for mAbs, and hydrophobicity and zeta-potential for HIC resins with high fit quality (adjusted R2 > 0.80). We identified zeta-potential as a novel key modeling parameter. When using these models to select a HIC resin for HMW clearance of a test mAb, we were able to achieve 60% HMW clearance and 89% recovery. These models can be used to expedite the downstream process development for mAbs in an industry setting.
Collapse
Affiliation(s)
- Douglas Nolan
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA.
| | - Thomas R Chin
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| | - Mick Eamsureya
- Eurofins Lancaster Laboratories Professional Scientific Services, LLC, Lancaster, PA, 17601, USA
| | | | - Olga Paley
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| | - Christina Alves
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| | - George Parks
- Takeda Pharmaceuticals America Inc, Lexington, MA, 02421, USA
| |
Collapse
|
6
|
Tang S, Tao J, Li Y. Challenges and solutions for the downstream purification of therapeutic proteins. Antib Ther 2024; 7:1-12. [PMID: 38235378 PMCID: PMC10791043 DOI: 10.1093/abt/tbad028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 10/27/2023] [Accepted: 11/15/2023] [Indexed: 01/19/2024] Open
Abstract
The innovation in recombinant protein technology has brought forth a host of challenges related to the purification of these therapeutic proteins. This article delves into the intricate landscape of developing purification processes for artificially designed therapeutic proteins. The key hurdles include controlling protein reduction, protein capture, ensuring stability, eliminating aggregates, removing host cell proteins and optimizing protein recovery. In this review, we outline the purification strategies in order to obtain products of high purity, highlighting the corresponding solutions to circumvent the unique challenges presented by recombinant therapeutic proteins, and exemplify the practical applications by case studies. Finally, a perspective towards future purification process development is provided.
Collapse
Affiliation(s)
- Shuo Tang
- GenScript ProBio Biotechnology Co., Ltd, Nanjing, Jiangsu 21100, P.R. China
| | - Jiaoli Tao
- GenScript ProBio Biotechnology Co., Ltd, Nanjing, Jiangsu 21100, P.R. China
| | - Ying Li
- GenScript ProBio Biotechnology Co., Ltd, Nanjing, Jiangsu 21100, P.R. China
| |
Collapse
|
7
|
Park E, Izadi S. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling. MAbs 2024; 16:2362788. [PMID: 38853585 PMCID: PMC11168226 DOI: 10.1080/19420862.2024.2362788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 05/29/2024] [Indexed: 06/11/2024] Open
Abstract
In silico assessment of antibody developability during early lead candidate selection and optimization is of paramount importance, offering a rapid and material-free screening approach. However, the predictive power and reproducibility of such methods depend heavily on the selection of molecular descriptors, model parameters, accuracy of predicted structure models, and conformational sampling techniques. Here, we present a set of molecular surface descriptors specifically designed for predicting antibody developability. We assess the performance of these descriptors by benchmarking their correlations with an extensive array of experimentally determined biophysical properties, including viscosity, aggregation, hydrophobic interaction chromatography, human pharmacokinetic clearance, heparin retention time, and polyspecificity. Further, we investigate the sensitivity of these surface descriptors to methodological nuances, such as the choice of interior dielectric constant, hydrophobicity scales, structure prediction methods, and the impact of conformational sampling. Notably, we observe systematic shifts in the distribution of surface descriptors depending on the structure prediction method used, driving weak correlations of surface descriptors across structure models. Averaging the descriptor values over conformational distributions from molecular dynamics mitigates the systematic shifts and improves the consistency across different structure prediction methods, albeit with inconsistent improvements in correlations with biophysical data. Based on our benchmarking analysis, we propose six in silico developability risk flags and assess their effectiveness in predicting potential developability issues for a set of case study molecules.
Collapse
Affiliation(s)
- Eliott Park
- Pharmaceutical Development, Genentech Inc, South San Francisco, CA, USA
| | - Saeed Izadi
- Pharmaceutical Development, Genentech Inc, South San Francisco, CA, USA
| |
Collapse
|
8
|
Blanch NB, Cascone O, Fingermann M. Selective immunoglobulin aggregates removal in antivenoms by a simple chromatographic step based on a monolithic stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci 2024; 1232:123978. [PMID: 38142501 DOI: 10.1016/j.jchromb.2023.123978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/29/2023] [Accepted: 12/17/2023] [Indexed: 12/26/2023]
Abstract
Antivenom therapy is a critical intervention for treating the more than 5.000.000 envenomation accidents that occur each year around the world. These immunotherapeutic drugs are mostly produced following techniques developed more than fifty years ago with minor changes. Aggregate content has been described as one of the main causes of early adverse effects after intravenous administration of antivenoms. In this work we propose the introduction of a final polishing step to traditional antivenom manufacturing processes aimed at lowering the aggregate content in the final product. The refinement step proposed in this work is based on the selective capture of immunoglobulin aggregates by a cation exchange monolithic stationary phase. We show that this media can effectively remove aggregates in the final product under isotonic ion-strength and mildly acidic conditions following a negative chromatography strategy, thus making it a useful technique for producing higher quality products.
Collapse
Affiliation(s)
- Nicolás Berardo Blanch
- Instituto Nacional de Producción de Biológicos, ANLIS "Dr. Carlos G. Malbrán", CABA, Av. Vélez, Sarsfield 563, (1282), Argentina
| | - Osvaldo Cascone
- Instituto Nacional de Producción de Biológicos, ANLIS "Dr. Carlos G. Malbrán", CABA, Av. Vélez, Sarsfield 563, (1282), Argentina; Instituto de Nanobiotecnología (NANOBIOTEC), CONICET-UBA, CABA (1113) Junín 956, Argentina
| | - Matías Fingermann
- Instituto Nacional de Producción de Biológicos, ANLIS "Dr. Carlos G. Malbrán", CABA, Av. Vélez, Sarsfield 563, (1282), Argentina.
| |
Collapse
|
9
|
Dilks AT, Gilchrist J, Lam Y, Nicholes N, Stanley B. Considerations for operational space definition and optimization of a no-salt flowthrough hydrophobic interaction chromatography purification step. Biotechnol Prog 2023; 39:e3351. [PMID: 37102582 DOI: 10.1002/btpr.3351] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 02/17/2023] [Accepted: 03/29/2023] [Indexed: 04/28/2023]
Abstract
No-salt flowthrough hydrophobic interaction chromatography (HIC) has been shown to effectively remove process and product-related impurities from bioprocess streams. In this publication, a panel of six antibodies has been used to demonstrate operating principles for the application of no-salt flowthrough HIC in antibody purification processes. The results indicate that no-salt flowthrough HIC provides robust aggregate clearance across operating conditions including flow rate, and variations in resin ligand density. Additionally, HMW reduction has an optimal pH range relative to the isoelectric point of each molecule and high molecular weight (HMW) reduction can be improved by altering the total protein load and/or HMW concentration to drive binding of high molecular weight species to the resin.
Collapse
Affiliation(s)
| | | | - Yik Lam
- Technical Development, Biogen Inc., Durham, North Carolina, USA
| | - Nathan Nicholes
- Technical Development, Biogen Inc., Durham, North Carolina, USA
| | - Brad Stanley
- Technical Development, Biogen Inc., Durham, North Carolina, USA
| |
Collapse
|
10
|
|
11
|
Aoyama S, Matsumoto Y, Mori C, Sota K. Application of novel mixed mode chromatography (MMC) resins having a hydrophobic modified polyallylamine ligand for monoclonal antibody purification. J Chromatogr B Analyt Technol Biomed Life Sci 2021; 1191:123072. [PMID: 35051681 DOI: 10.1016/j.jchromb.2021.123072] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 11/16/2021] [Accepted: 11/26/2021] [Indexed: 11/16/2022]
Abstract
Polyallylamine (PAA) has been utilized as a salt tolerant anion exchange chromatography ligand in downstream processing of biopharmaceuticals. We have developed novel MMC resins based on PAA polymer ligand partially modified with hydrophobic butyl or phenyl group. The resulting hydrophobic modified PAA ligand reduced HCP level to 12% (21-23 ppm) under 6 mS/cm in a flow-through polishing step of mAb, while not modified PAA ligand showed only 79% (145 ppm). We also found that structure of hydrophobic groups in the ligand mainly influenced on mAb yield. That is 25% increase of phenyl group modification ratio reduces mAb yield from 95% to 90%. On the other hand, modification with butyl group kept mAb yield more than 95%. The optimized ligand structure displayed a wide operational conductivity range. Extended purification studies of mAb using the MMC resin in the flow-through polishing step were carried out under optimized pH and conductivity condition as determined in a DOE study. The study revealed that the MMC resin was effective for developing one-step flow-through polishing workflow for mAb purification. In addition, the MMC flow-through polishing step could be directly coupled with a specified CEX chromatography step to efficiently remove mAb aggregates from 2.3% to <1.0% to achieve a biopharmaceutical-grade quality and a high yield of mAb (>93%) with a high loading capacity around 1000 mg/mL-resin. This new MMC resin will be useful in future mAb manufacturing platforms comprising of a robust and cost-effective flow-through polishing step.
Collapse
Affiliation(s)
- Shigeyuki Aoyama
- Minamata Factory, JNC Corporation, 1-1 Noguchi-cho, Minamata-shi, Kumamoto 867-8501, Japan
| | - Yoshihiro Matsumoto
- Yokohama Research Center, JNC Corporation, 5-1 Ookawa, Kanazawa-ku, Yokohama-shi Kanagawa 236-8605, Japan.
| | - Chigusa Mori
- Yokohama Research Center, JNC Corporation, 5-1 Ookawa, Kanazawa-ku, Yokohama-shi Kanagawa 236-8605, Japan
| | - Kojiro Sota
- Yokohama Research Center, JNC Corporation, 5-1 Ookawa, Kanazawa-ku, Yokohama-shi Kanagawa 236-8605, Japan
| |
Collapse
|
12
|
Matsuda Y, Mendelsohn BA. Recent Advances in Drug-Antibody Ratio Determination of Antibody-Drug Conjugates. Chem Pharm Bull (Tokyo) 2021; 69:976-983. [PMID: 34602579 DOI: 10.1248/cpb.c21-00258] [Citation(s) in RCA: 29] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Antibody-drug conjugates (ADCs) are biopharmaceuticals produced by chemically linking small molecules (payloads) to antibodies that possess specific affinity for the target cell. The ADCs currently on the commercially market are the result of a stochastic conjugation of highly-potent payloads to multiple sites on the monoclonal antibody, resulting in a heterogeneous drug-antibody ratio (DAR) and drug distribution. The heterogeneity inherent to ADCs not produced site-specifically may not only be detrimental to the quality of the drug but also is less-desirable from the perspective of regulatory science. An ideal method or unified approach used to measure the DAR for ADCs, a critical aspect of their analysis and characterization, has not yet been established in the ADC field and remains an often-challenging issue for bioanalytical chemists. In this review we describe, compare, and evaluate the characteristics of various DAR determination methods for ADCs featuring recently reported technologies. The future landscape of bioconjugate DAR analysis is also discussed.
Collapse
|
13
|
Matsuda Y. Current approaches for the purification of antibody-drug conjugates. J Sep Sci 2021; 45:27-37. [PMID: 34473399 DOI: 10.1002/jssc.202100575] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2021] [Revised: 08/27/2021] [Accepted: 08/28/2021] [Indexed: 01/21/2023]
Abstract
In the past two decades, antibody-drug conjugates have gained increasing attention because they expand the therapeutic index when compared with that of traditional chemotherapies. Antibody-drug conjugates are highly complex structures consisting of antibodies covalently conjugated with small-molecule cytotoxic drugs. The complex structure of antibody-drug conjugates makes chemistry, manufacturing, and control difficult. In contrast to antibody production, distinct purification methods following conjugation of antibodies with drug-linkers are required for the manufacturing. For process development of antibody drug conjugates, the drug-to-antibody ratio, free drug-linkers, and aggregates are critical quality attributes that must be strictly controlled and removed by appropriate purification techniques. In this review, features of various purification methods used to purify antibody drug conjugates are described and evaluated. The future landscape of the antibody-conjugates field is also discussed briefly.
Collapse
|
14
|
Abstract
In the past 30 years, highly specific drugs, known as antibodies, have conquered the biopharmaceutical market. In addition to monoclonal antibodies (mAbs), antibody fragments are successfully applied. However, recombinant production faces challenges. Process analytical tools for monitoring and controlling production processes are scarce and time-intensive. In the downstream process (DSP), affinity ligands are established as the primary and most important step, while the application of other methods is challenging. The use of these affinity ligands as monitoring tools would enable a platform technology to monitor process steps in the USP and DSP. In this review, we highlight the current applications of affinity ligands (proteins A, G, and L) and discuss further applications as process analytical tools.
Collapse
|
15
|
Kruse T, Kampmann M, Rüddel I, Greller G. An alternative downstream process based on aqueous two-phase extraction for the purification of monoclonal antibodies. Biochem Eng J 2020. [DOI: 10.1016/j.bej.2020.107703] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
16
|
Chandra P, Enespa, Singh R, Arora PK. Microbial lipases and their industrial applications: a comprehensive review. Microb Cell Fact 2020; 19:169. [PMID: 32847584 PMCID: PMC7449042 DOI: 10.1186/s12934-020-01428-8] [Citation(s) in RCA: 265] [Impact Index Per Article: 66.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Accepted: 08/17/2020] [Indexed: 12/12/2022] Open
Abstract
Lipases are very versatile enzymes, and produced the attention of the several industrial processes. Lipase can be achieved from several sources, animal, vegetable, and microbiological. The uses of microbial lipase market is estimated to be USD 425.0 Million in 2018 and it is projected to reach USD 590.2 Million by 2023, growing at a CAGR of 6.8% from 2018. Microbial lipases (EC 3.1.1.3) catalyze the hydrolysis of long chain triglycerides. The microbial origins of lipase enzymes are logically dynamic and proficient also have an extensive range of industrial uses with the manufacturing of altered molecules. The unique lipase (triacylglycerol acyl hydrolase) enzymes catalyzed the hydrolysis, esterification and alcoholysis reactions. Immobilization has made the use of microbial lipases accomplish its best performance and hence suitable for several reactions and need to enhance aroma to the immobilization processes. Immobilized enzymes depend on the immobilization technique and the carrier type. The choice of the carrier concerns usually the biocompatibility, chemical and thermal stability, and insolubility under reaction conditions, capability of easy rejuvenation and reusability, as well as cost proficiency. Bacillus spp., Achromobacter spp., Alcaligenes spp., Arthrobacter spp., Pseudomonos spp., of bacteria and Penicillium spp., Fusarium spp., Aspergillus spp., of fungi are screened large scale for lipase production. Lipases as multipurpose biological catalyst has given a favorable vision in meeting the needs for several industries such as biodiesel, foods and drinks, leather, textile, detergents, pharmaceuticals and medicals. This review represents a discussion on microbial sources of lipases, immobilization methods increased productivity at market profitability and reduce logistical liability on the environment and user.
Collapse
Affiliation(s)
- Prem Chandra
- Food Microbiology & Toxicology, Department of Microbiology, School for Biomedical and Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central) University, Lucknow, Uttar Pradesh 226025 India
| | - Enespa
- Department of Plant Pathology, School for Agriculture, SMPDC, University of Lucknow, Lucknow, 226007 U.P. India
| | - Ranjan Singh
- Department of Environmental Science, School for Environmental Science, Babasaheb Bhimrao Ambedkar University (A Central) University, Lucknow, U.P. India
| | - Pankaj Kumar Arora
- Department of Microbiology, School for Biomedical and Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central) University, Lucknow, U.P. India
| |
Collapse
|
17
|
Pereira Bresolin IRA, Lingg N, Bresolin ITL, Jungbauer A. Hydrophobic interaction chromatography as polishing step enables obtaining ultra-pure recombinant antibodies. J Biotechnol 2020; 324S:100020. [PMID: 34154739 DOI: 10.1016/j.btecx.2020.100020] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 05/04/2020] [Accepted: 05/16/2020] [Indexed: 01/04/2023]
Abstract
Hydrophobic interaction chromatography is a versatile method to polish antibodies. Here, we present a polishing procedure in order to obtain an ultra-pure preparation of antitumor necrosis factor (TNF) alpha IgG1. Hydrophobic interaction chromatography (HIC) was used with Toyopearl® Phenyl 650M adsorbent in the presence of ammonium sulfate. Adsorption isotherms, breakthrough curves and chromatographic runs were carried out. The eluted antibody was recovered with 99.9 % purity and 96.2 % yield. In the main peak, aggregates, host cell proteins (HCP) and DNA content were below the limit of detection of the analytical methods used. Thus, the method proposed here shows potential to be employed in a downstream process when an ultra-pure antibody preparation is required.
Collapse
Affiliation(s)
- Iara Rocha Antunes Pereira Bresolin
- Chemical Engineering Department, Federal University of São Paulo, Diadema, SP, Brazil; Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Nico Lingg
- Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria
| | - Igor Tadeu Lazzarotto Bresolin
- Chemical Engineering Department, Federal University of São Paulo, Diadema, SP, Brazil; Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria
| | - Alois Jungbauer
- Institute of Bioprocess Science and Engineering, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology (ACIB), Vienna, Austria.
| |
Collapse
|
18
|
A Purification Strategy Utilizing Hydrophobic Interaction Chromatography to Obtain Homogeneous Species from a Site-Specific Antibody Drug Conjugate Produced by AJICAP™ First Generation. Antibodies (Basel) 2020; 9:antib9020016. [PMID: 32443479 PMCID: PMC7344391 DOI: 10.3390/antib9020016] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2020] [Revised: 04/20/2020] [Accepted: 04/22/2020] [Indexed: 12/14/2022] Open
Abstract
In recent years, site-specific antibody drug conjugates (ADC)s have been in great demand because they have an expanded therapeutic index compared with conventional ADCs. AJICAP™ technology is a chemical conjugation platform to obtain site-specific ADCs through the use of a class of Fc-affinity compounds. Promising results from early technology development studies led to further investigation of AJICAP™ ADC materials to obtain site-specific and homogeneous drug antibody ratio (DAR) ADCs. Here we report site-specific conjugation followed by a preparative hydrophobic interaction chromatography (HIC) purification strategy to obtain purified “DAR = 1.0” and “DAR = 2.0” AJICAP™ ADC materials. Optimization of the mobile phase conditions and resin achieved a high recovery rate. In vitro biological assay demonstrated the target selective activity for purified homogeneous DAR ADCs. These results indicate the ability of a HIC purification strategy to provide “DAR = 1.0” and “DAR = 2.0” AJICAP™ ADCs with considerable potency and target selectivity.
Collapse
|
19
|
Willis LF, Kumar A, Jain T, Caffry I, Xu Y, Radford SE, Kapur N, Vásquez M, Brockwell DJ. The uniqueness of flow in probing the aggregation behavior of clinically relevant antibodies. ENGINEERING REPORTS : OPEN ACCESS 2020; 2:e12147. [PMID: 34901768 PMCID: PMC8638667 DOI: 10.1002/eng2.12147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Revised: 02/18/2020] [Accepted: 02/19/2020] [Indexed: 06/10/2023]
Abstract
The development of therapeutic monoclonal antibodies (mAbs) can be hindered by their tendency to aggregate throughout their lifetime, which can illicit immunogenic responses and render mAb manufacturing unfeasible. Consequently, there is a need to identify mAbs with desirable thermodynamic stability, solubility, and lack of self-association. These behaviors are assessed using an array of in silico and in vitro assays, as no single assay can predict aggregation and developability. We have developed an extensional and shear flow device (EFD), which subjects proteins to defined hydrodynamic forces which mimic those experienced in bioprocessing. Here, we utilize the EFD to explore the aggregation propensity of 33 IgG1 mAbs, whose variable domains are derived from clinical antibodies. Using submilligram quantities of material per replicate, wide-ranging EFD-induced aggregation (9-81% protein in pellet) was observed for these mAbs, highlighting the EFD as a sensitive method to assess aggregation propensity. By comparing the EFD-induced aggregation data to those obtained previously from 12 other biophysical assays, we show that the EFD provides distinct information compared with current measures of adverse biophysical behavior. Assessing a candidate's liability to hydrodynamic force thus adds novel insight into the rational selection of developable mAbs that complements other assays.
Collapse
Affiliation(s)
- Leon F. Willis
- School of Molecular and Cellular Biology, Faculty of Biological SciencesUniversity of LeedsLeedsUK
- Astbury Centre for Structural Molecular BiologyUniversity of LeedsLeedsUK
| | - Amit Kumar
- School of Molecular and Cellular Biology, Faculty of Biological SciencesUniversity of LeedsLeedsUK
- Astbury Centre for Structural Molecular BiologyUniversity of LeedsLeedsUK
- Department of Life SciencesImperial College LondonLondonUK
| | | | - Isabelle Caffry
- Adimab LLCLebanonNew HampshireUSA
- Cornell Johnson Graduate School of ManagementIthacaNew YorkUSA
| | - Yingda Xu
- Adimab LLCLebanonNew HampshireUSA
- Biotheus Inc.ZhuhaiGuangdong ProvinceChina
| | - Sheena E. Radford
- School of Molecular and Cellular Biology, Faculty of Biological SciencesUniversity of LeedsLeedsUK
- Astbury Centre for Structural Molecular BiologyUniversity of LeedsLeedsUK
| | - Nikil Kapur
- School of Mechanical Engineering, Faculty of EngineeringUniversity of LeedsLeedsUK
| | | | - David J. Brockwell
- School of Molecular and Cellular Biology, Faculty of Biological SciencesUniversity of LeedsLeedsUK
- Astbury Centre for Structural Molecular BiologyUniversity of LeedsLeedsUK
| |
Collapse
|
20
|
Mechanistic modeling based process development for monoclonal antibody monomer-aggregate separations in multimodal cation exchange chromatography. J Chromatogr A 2019; 1602:317-325. [DOI: 10.1016/j.chroma.2019.05.056] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2019] [Revised: 05/25/2019] [Accepted: 05/28/2019] [Indexed: 11/18/2022]
|
21
|
Streamlining the polishing step development process via physicochemical characterization of monoclonal antibody aggregates. J Chromatogr A 2019; 1598:101-112. [DOI: 10.1016/j.chroma.2019.03.044] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2018] [Revised: 03/08/2019] [Accepted: 03/21/2019] [Indexed: 01/07/2023]
|
22
|
Kangwa M, Yelemane V, Ponnurangam A, Fernández-Lahore M. An engineered Staphylococcal Protein A based ligand: Production, characterization and potential application for the capture of Immunoglobulin and Fc-fusion proteins. Protein Expr Purif 2018; 155:27-34. [PMID: 30445097 DOI: 10.1016/j.pep.2018.11.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2018] [Revised: 11/12/2018] [Accepted: 11/12/2018] [Indexed: 12/28/2022]
Abstract
In antibody purification processes, affinity chromatography has been used with Staphylococcus aureus protein A (SpA) as the main ligand. In this work, we present a novel Staphylococcal Protein A (AviPure thereafter), a synthetic ligand analogue based on native SpA B domain, with a molecular weight of approximately 14 kDa. The binding affinity of mAbs to AviPure was evaluated using Surface Plasmon Resonance (SPR) and affinity chromatography methods. The equilibrium dissociation constant (KD) between the AviPure and mAbs was systematically measured using 1:1 (Langmuir) model and found to be 4.7 × 10-8 M, with constant of dissociation at kd ≤ 1.0 × 10-3 s-1 and ka being 3.1 × 104 M-1 s-1. When immobilized on Sepharose, the AviPure ligand density was 429 nmol/g moist weight resin and was able to effectively bind immunoglobulin and Fc fragment samples with higher affinity and the most effective flow rate when using ligand - Sepharose beads was at 75 cm/h giving the dynamic binding capacity of 53 mg/mL and 91% recovery of IgG. Suitable ligands used in affinity purification should have a KD ≤ 10-6 M and a dissociation rate (ka) averaging 10-3 M-1 s-1 with the kd ranging between 103 - 108 M-1. Therefore, the AviPure ligand can be used as an alternative to the standard protein A ligand in the purification of mAbs and Fc-fused proteins.
Collapse
Affiliation(s)
- Martin Kangwa
- Downstream Bioprocessing Laboratory, Department of Life Sciences & Chemistry, Jacobs University, Campus Ring 1, D-28759, Bremen, Germany.
| | - Vikas Yelemane
- Downstream Bioprocessing Laboratory, Department of Life Sciences & Chemistry, Jacobs University, Campus Ring 1, D-28759, Bremen, Germany
| | - Adilah Ponnurangam
- Downstream Bioprocessing Laboratory, Department of Life Sciences & Chemistry, Jacobs University, Campus Ring 1, D-28759, Bremen, Germany
| | - Marcelo Fernández-Lahore
- Downstream Bioprocessing Laboratory, Department of Life Sciences & Chemistry, Jacobs University, Campus Ring 1, D-28759, Bremen, Germany.
| |
Collapse
|
23
|
Andrade C, Arnold L, Motabar D, Aspelund M, Tang A, Hunter A, Chung WK. An Integrated Approach to Aggregate Control for Therapeutic Bispecific Antibodies Using an Improved Three Column Mab Platform-Like Purification Process. Biotechnol Prog 2018; 35:e2720. [PMID: 30298991 PMCID: PMC6667909 DOI: 10.1002/btpr.2720] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2018] [Revised: 09/17/2018] [Accepted: 09/17/2018] [Indexed: 12/23/2022]
Abstract
Single chain variable fragment‐IgGs (scFv‐IgG) are a class of bispecific antibodies consisting of two single chain variable fragments (scFv) that are fused to an intact IgG molecule. A common trend observed for expression of scFv‐IgGs in mammalian cell culture is a higher level of aggregates (10%–30%) compared to mAbs, which results in lower purification yields in order to meet product quality targets. Furthermore, the high aggregate levels also pose robustness risks to a conventional mAb three column platform purification process which uses only the polishing steps (e.g., cation exchange chromatography [CEX]) for aggregate removal. Protein A chromatography with pH gradient elution, high performance tangential flow filtration (HP‐TFF) and calcium phosphate precipitation were evaluated at the bench scale as means of introducing orthogonal aggregate removal capabilities into other aspects of the purification process. The two most promising process variants, namely Protein A pH gradient elution followed by calcium phosphate precipitation were evaluated at pilot scale, demonstrating comparable performance. Implementing Protein A chromatography with gradient elution and/or calcium phosphate precipitation removed a sufficient portion of the aggregate burden prior to the CEX polishing step, enabling CEX to be operated robustly under conditions favoring higher monomer yield. From starting aggregate levels ranging from 15% to 23% in the condition media, levels were reduced to between 2% and 3% at the end of the CEX step. The overall yield for the optimal process was 71%. Results of this work suggest an improved three‐column mAb platform‐like purification process for purification of high aggregate scFv‐IgG bispecific antibodies is feasible. © 2018 The Authors. Biotechnology Progress published by Wiley Periodicals, Inc. on behalf of American Institute of Chemical Engineers. Biotechnol. Prog., 35: e2720, 2019
Collapse
Affiliation(s)
- Cassia Andrade
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Lindsay Arnold
- Process Development Engineering, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Dana Motabar
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Matthew Aspelund
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Alison Tang
- Purification Process Sciences, MedImmune LLC, Cambridge, U.K
| | - Alan Hunter
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| | - Wai Keen Chung
- Purification Process Sciences, MedImmune LLC, One MedImmune Way, Gaithersburg, Maryland, 20878
| |
Collapse
|
24
|
Hall T, Kelly GM, Emery WR. Use of mobile phase additives for the elution of bispecific and monoclonal antibodies from phenyl based hydrophobic interaction chromatography resins. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1096:20-30. [PMID: 30130673 DOI: 10.1016/j.jchromb.2018.07.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Revised: 07/05/2018] [Accepted: 07/21/2018] [Indexed: 11/19/2022]
Abstract
Hydrophobic interaction chromatography (HIC) is routinely used in the purification of biopharmaceuticals such as antibodies. However, hydrophobic proteins can be difficult to elute resulting in low recovery of product thereby complicating early phase process development and potentially excluding the use of HIC resins for their manufacture. Mobile phase additives such as hexylene glycol and arginine facilitate protein elution from resins including HIC; therefore, these additives were evaluated toward the recovery and purification of bispecific and monoclonal antibodies from Phenyl Sepharose HP and Capto Phenyl ImpRes resins. The influences of gradient versus step elution as well as superficial linear velocity on product quality were evaluated. Improved protein recovery and reduction of both soluble product aggregate and host cell protein were observed for the tested antibodies with both hexylene glycol and arginine. Furthermore, the impact of salt removal from the HIC load on protein-resin binding was examined providing opportunities to minimize processing time. This method was successfully scaled using a Phenyl Sepharose HP (5 cm i.d. × 20.0 cm) and Capto Phenyl ImpRes (3.2 cm i.d. × 21.4 cm) column demonstrating potential for manufacturing purposes.
Collapse
Affiliation(s)
- Troii Hall
- Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285-0001, USA.
| | - Gerard M Kelly
- Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285-0001, USA.
| | - Warren R Emery
- Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285-0001, USA.
| |
Collapse
|
25
|
Recent developments in chromatographic purification of biopharmaceuticals. Biotechnol Lett 2018; 40:895-905. [DOI: 10.1007/s10529-018-2552-1] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2018] [Accepted: 04/03/2018] [Indexed: 02/07/2023]
|
26
|
Creasy A, Lomino J, Barker G, Khetan A, Carta G. Gradient elution behavior of proteins in hydrophobic interaction chromatography with U-shaped retention factor curves. J Chromatogr A 2018; 1547:53-61. [DOI: 10.1016/j.chroma.2018.03.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2018] [Revised: 02/16/2018] [Accepted: 03/07/2018] [Indexed: 11/24/2022]
|
27
|
Brinkmann A, Elouafiq S, Pieracci J, Westoby M. Leveraging single-pass tangential flow filtration to enable decoupling of upstream and downstream monoclonal antibody processing. Biotechnol Prog 2018; 34:405-411. [DOI: 10.1002/btpr.2601] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 12/10/2017] [Indexed: 11/08/2022]
Affiliation(s)
- Alex Brinkmann
- Biopharmaceutical Development, Biogen; Research Triangle Park NC 27709
| | - Sanaa Elouafiq
- Biopharmaceutical Development, Biogen; Research Triangle Park NC 27709
| | - John Pieracci
- Biopharmaceutical Development, Biogen; Cambridge MA 02142
| | - Matthew Westoby
- Biopharmaceutical Development, Biogen; Research Triangle Park NC 27709
| |
Collapse
|
28
|
Ichihara T, ITO T, Kurisu Y, Galipeau K, Gillespie C. Integrated flow-through purification for therapeutic monoclonal antibodies processing. MAbs 2018; 10:325-334. [PMID: 29271693 PMCID: PMC5825194 DOI: 10.1080/19420862.2017.1417717] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 11/30/2017] [Accepted: 12/08/2017] [Indexed: 11/08/2022] Open
Abstract
An integrated all flow-through technology platform for the purification of therapeutic monoclonal antibodies (mAb), consisting of activated carbon and flow-through cation and anion exchange chromatography steps, can replace a conventional chromatography platform. This new platform was observed to have excellent impurity clearance at high mAb loadings with overall mAb yield exceeding 80%. Robust removal of DNA and host cell protein was demonstrated by activated carbon and a new flow-through cation exchange resin exhibited excellent clearance of mAb aggregate with high monomer recoveries. A ten-fold improvement of mAb loading was achieved compared to a traditional cation exchange resin designed for bind and elute mode. High throughput 96-well plate screening was used for process optimization, focusing on mAb loading and solution conditions. Optimum operating windows for integrated flow-through purification are proposed based on performance characteristics. The combination of an all flow-through polishing process presents significant opportunities for improvements in facility utilization and process economics.
Collapse
Affiliation(s)
| | - Takao ITO
- Process solutions, Merck Ltd., DiverCity Tokyo Office Tower 15F, 1-1-20 Aomi, Koto-ku, Tokyo, Japan
| | - Yasuhiko Kurisu
- Process solutions, Merck Ltd., DiverCity Tokyo Office Tower 15F, 1-1-20 Aomi, Koto-ku, Tokyo, Japan
| | | | | |
Collapse
|
29
|
Johnson SA, Walsh A, Brown MR, Lute SC, Roush DJ, Burnham MS, Brorson KA. The step-wise framework to design a chromatography-based hydrophobicity assay for viral particles. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1061-1062:430-437. [DOI: 10.1016/j.jchromb.2017.08.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 07/26/2017] [Accepted: 08/02/2017] [Indexed: 02/06/2023]
|
30
|
Shukla AA, Wolfe LS, Mostafa SS, Norman C. Evolving trends in mAb production processes. Bioeng Transl Med 2017; 2:58-69. [PMID: 29313024 PMCID: PMC5689530 DOI: 10.1002/btm2.10061] [Citation(s) in RCA: 138] [Impact Index Per Article: 19.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2016] [Revised: 02/24/2017] [Accepted: 03/06/2017] [Indexed: 12/30/2022] Open
Abstract
Monoclonal antibodies (mAbs) have established themselves as the leading biopharmaceutical therapeutic modality. The establishment of robust manufacturing platforms are key for antibody drug discovery efforts to seamlessly translate into clinical and commercial successes. Several drivers are influencing the design of mAb manufacturing processes. The advent of biosimilars is driving a desire to achieve lower cost of goods and globalize biologics manufacturing. High titers are now routinely achieved for mAbs in mammalian cell culture. These drivers have resulted in significant evolution in process platform approaches. Additionally, several new trends in bioprocessing have arisen in keeping with these needs. These include the consideration of alternative expression systems, continuous biomanufacturing and non-chromatographic separation formats. This paper discusses these drivers in the context of the kinds of changes they are driving in mAb production processes.
Collapse
Affiliation(s)
| | - Leslie S. Wolfe
- Process Development & ManufacturingKBI Biopharma Inc.DurhamNC27704
| | - Sigma S. Mostafa
- Process Development & ManufacturingKBI Biopharma Inc.DurhamNC27704
| | - Carnley Norman
- Process Development & ManufacturingKBI Biopharma Inc.DurhamNC27704
| |
Collapse
|
31
|
Zhang J, Conley L, Pieracci J, Ghose S. Pool-less processing to streamline downstream purification of monoclonal antibodies. Eng Life Sci 2017; 17:117-124. [PMID: 32624758 PMCID: PMC6999506 DOI: 10.1002/elsc.201600104] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2016] [Revised: 06/14/2016] [Accepted: 07/05/2016] [Indexed: 11/10/2022] Open
Abstract
With cell culture titers and productivity increasing in the last few years, pressure has been placed on downstream purification to look at alternative strategies to meet the demand of biotech products with high dose requirements. Even when the upstream process is not continuous (perfusion based), adopting a more productive and/or continuous downstream process can be of significant advantage. Due to the recent trend in exploring continuous processing options for biomolecules, several enabling technologies have been assessed at Biogen. In this paper, we evaluate the capability of one of these technologies to streamline and improve our downstream mAb purification platform. Current conventional downstream polishing steps at Biogen are operated in flow-through mode to achieve higher loadings while maintaining good selectivity. As titers increase, this would result in larger columns and larger intermediate product pool holding tanks. A semicontinuous downstream process linking the second and third chromatography steps in tandem can reduce/eliminate intermediate holding tanks, reduce overall processing time, and combine unit operations to reduce validation burdens. A pool-less processing technology utilizing inline adjustment functionality was evaluated to address facility fit challenges for three high titer mAbs. Two different configurations of polishing steps were examined: (i) anion exchange and hydrophobic interaction and (ii) anion exchange and mixed mode chromatography. Initial laboratory scale proof of concept studies showed comparable performance between the batch purification process and the pool-less process configuration.
Collapse
Affiliation(s)
- Jennifer Zhang
- Department of Process Biochemistry, BiogenResearch Triangle ParkNCUSA
| | - Lynn Conley
- Department of Process Biochemistry, BiogenResearch Triangle ParkNCUSA
| | - John Pieracci
- Department of Process BiochemistryBiogenCambridgeMAUSA
| | - Sanchayita Ghose
- Department of Process Biochemistry, BiogenResearch Triangle ParkNCUSA
| |
Collapse
|
32
|
Liu Z, Wickramasinghe SR, Qian X. The architecture of responsive polymeric ligands on protein binding and recovery. RSC Adv 2017. [DOI: 10.1039/c7ra01499f] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Ligand design and optimization are critical for protein purification during downstream processing.
Collapse
Affiliation(s)
- Zizhao Liu
- Department of Chemical Engineering
- University of Arkansas
- Fayetteville
- USA
| | | | - Xianghong Qian
- Department of Biomedical Engineering
- University of Arkansas
- Fayetteville
- USA
| |
Collapse
|
33
|
Astefanei A, Dapic I, Camenzuli M. Different Stationary Phase Selectivities and Morphologies for Intact Protein Separations. Chromatographia 2016; 80:665-687. [PMID: 28529348 PMCID: PMC5413533 DOI: 10.1007/s10337-016-3168-z] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Revised: 08/17/2016] [Accepted: 09/06/2016] [Indexed: 12/18/2022]
Abstract
The central dogma of biology proposed that one gene encodes for one protein. We now know that this does not reflect reality. The human body has approximately 20,000 protein-encoding genes; each of these genes can encode more than one protein. Proteins expressed from a single gene can vary in terms of their post-translational modifications, which often regulate their function within the body. Understanding the proteins within our bodies is a key step in understanding the cause, and perhaps the solution, to disease. This is one of the application areas of proteomics, which is defined as the study of all proteins expressed within an organism at a given point in time. The human proteome is incredibly complex. The complexity of biological samples requires a combination of technologies to achieve high resolution and high sensitivity analysis. Despite the significant advances in mass spectrometry, separation techniques are still essential in this field. Liquid chromatography is an indispensable tool by which low-abundant proteins in complex samples can be enriched and separated. However, advances in chromatography are not as readily adapted in proteomics compared to advances in mass spectrometry. Biologists in this field still favour reversed-phase chromatography with fully porous particles. The purpose of this review is to highlight alternative selectivities and stationary phase morphologies that show potential for application in top-down proteomics; the study of intact proteins.
Collapse
Affiliation(s)
- A. Astefanei
- Centre for Analytical Science in Amsterdam (CASA), Van’t Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands
| | - I. Dapic
- Centre for Analytical Science in Amsterdam (CASA), Van’t Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands
| | - M. Camenzuli
- Centre for Analytical Science in Amsterdam (CASA), Van’t Hoff Institute for Molecular Sciences, University of Amsterdam, Science Park 904, 1098 XH Amsterdam, The Netherlands
| |
Collapse
|
34
|
Liu Z, Wickramasinghe SR, Qian X. Membrane chromatography for protein purifications from ligand design to functionalization. SEP SCI TECHNOL 2016. [DOI: 10.1080/01496395.2016.1223133] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Affiliation(s)
- Zizhao Liu
- Department of Chemical Engineering, University of Arkansas, Fayetteville, Arkansas, USA
| | | | - Xianghong Qian
- Department of Biomedical Engineering, University of Arkansas, Fayetteville, Arkansas, USA
| |
Collapse
|
35
|
Development of an acidic/neutral antibody flow-through polishing step using salt-tolerant anion exchange chromatography. ACTA ACUST UNITED AC 2015. [DOI: 10.4155/pbp.15.28] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
Liang Y, Chen S, Zhu J, Zhou X, Yang C, Yao L, Zhang C. Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies. Bosn J Basic Med Sci 2015; 15:42-9. [PMID: 26042512 DOI: 10.17305/bjbms.2015.300] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Revised: 03/03/2015] [Accepted: 03/04/2015] [Indexed: 01/16/2023] Open
Abstract
The aim of our study was to determine the role of dystrophin hydrophobic regions in the pathogenesis of Duchenne (DMD) and Becker (BMD) muscular dystrophies, by the Kyte-Doolittle scale mean hydrophobicity profile and 3D molecular models. A total of 1038 cases diagnosed with DMD or BMD with the in-frame mutation were collected in our hospital and the Leiden DMD information database in the period 2002-2013. Correlation between clinical types and genotypes were determined on the basis of these two sources. In addition, the Kyte-Doolittle scale mean hydrophobicity of dystrophin was analyzed using BioEdit software and the models of the hydrophobic domains of dystrophin were constructed. The presence of four hydrophobic regions is confirmed. They include the calponin homology CH2 domain on the actin-binding domain (ABD), spectrin-type repeat 16, hinge III and the EF Hand domain. The severe symptoms of DMD usually develop as a result of the mutational disruption in the hydrophobic regions I, II and IV of dystrophin - those that bind associated proteins of the dystrophin-glycoprotein complex (DGC). On the other hand, when the hydrophobic region III is deleted, the connection of the ordered repeat domains of the central rod domain remains intact, resulting in the less severe clinical presentation. We conclude that mutational changes in the structure of hydrophobic regions of dystrophin play an important role in the pathogenesis of DMD.
Collapse
Affiliation(s)
- Yingyin Liang
- Department of Neurology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province.
| | | | | | | | | | | | | |
Collapse
|
37
|
Bresolin IRAP, Bresolin ITL, Pessoa A. Purification of Anti-Interleukin-6 Monoclonal Antibody Using Precipitation and Immobilized Metal-Ion Affinity Chromatography. ADSORPT SCI TECHNOL 2015. [DOI: 10.1260/0263-6174.33.2.191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Affiliation(s)
- Iara Rocha Antunes Pereira Bresolin
- Department of Biochemical and Pharmaceutical Technology, University of São Paulo (USP), Professor Lineu Prestes Avenue, 580 São Paulo, São Paulo 05508-000, Brazil
- Department of Exact and Earth Sciences, Federal University of São Paulo (UNIFESP), Campus Diadema, Diadema, São Paulo 09972-270, Brazil
| | - Igor Tadeu Lazzarotto Bresolin
- Department of Exact and Earth Sciences, Federal University of São Paulo (UNIFESP), Campus Diadema, Diadema, São Paulo 09972-270, Brazil
| | - Adalberto Pessoa
- Department of Biochemical and Pharmaceutical Technology, University of São Paulo (USP), Professor Lineu Prestes Avenue, 580 São Paulo, São Paulo 05508-000, Brazil
| |
Collapse
|
38
|
Kumar V, Rathore AS. Two-stage chromatographic separation of aggregates for monoclonal antibody therapeutics. J Chromatogr A 2014; 1368:155-62. [DOI: 10.1016/j.chroma.2014.09.077] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2014] [Revised: 09/17/2014] [Accepted: 09/27/2014] [Indexed: 10/24/2022]
|
39
|
Salt-independent hydrophobic displacement chromatography for antibody purification using cyclodextrin as supermolecular displacer. J Chromatogr A 2014; 1369:98-104. [DOI: 10.1016/j.chroma.2014.10.009] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 10/01/2014] [Accepted: 10/05/2014] [Indexed: 11/19/2022]
|
40
|
Human IgG adsorption using dye-ligand epoxy chitosan/alginate as adsorbent: influence of buffer system. ADSORPTION 2014. [DOI: 10.1007/s10450-014-9636-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|